Novo Nordisk to Acquire Dicerna

Pharma news update 29/11/2021

Dicerna Pharmaceuticals, Inc. announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of 80% to Dicerna’s closing price on November 17, 2021. The transaction was unanimously approved by the Dicerna Board of Directors and the Board of Directors of Novo Nordisk.

Novo Nordisk and Dicerna have been parties to a research collaboration since 2019 to discover and develop RNAi therapies using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets with the potential to deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. Novo Nordisk expects to initiate clinical development of the first investigational RNAi therapeutic to emerge from this collaboration in 2022.

Dicerna’s RNAi technology platform enables access to intracellular disease targets across hepatic and extrahepatic cell and tissue types, complementing Novo Nordisk’s existing technology platforms. This acquisition supports Novo Nordisk’s strategy of developing and applying a broad range of technology platforms across all Novo Nordisk therapeutic areas.

“The acquisition of Dicerna accelerates Novo Nordisk’s research within RNAi and expands the usage of the RNAi technology,” said Marcus Schindler, Executive Vice President and Chief Scientific Officer of Novo Nordisk. “We build on our successful collaboration and by combining Dicerna’s state-of-the-art RNAi drug engine and intracellular delivery with our deep capabilities in disease biology understanding and tissue targeting through peptides and proteins we have the potential to expand our pipeline and deliver life-changing precision medicines for people living with chronic diseases such as diabetes, obesity, cardiovascular disease and NASH, as well as rare diseases like endocrine disorders and bleeding disorders.”

“Since the start of our collaboration two years ago, the Dicerna and Novo Nordisk teams have established a strong rapport built on a foundation of mutual respect for one another’s capabilities, culture and expertise,” said Douglas Fambrough, Ph.D., Founder, President and Chief Executive Officer of Dicerna. “The combination of Dicerna’s expertise in RNAi and oligonucleotide therapeutics and highly skilled employees with Novo Nordisk’s industry leadership in developing and commercializing medicines to treat serious chronic diseases has the potential to significantly accelerate and expand our mission to deliver GalXC RNAi therapies for the benefit of patients and all our stakeholders.”

Tags : #NovoNordisk #Dicerna #RnaiPlatform #MarcusSchindler

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Advancing Healthcare Access: ScreenHer initiative in Pakistan close to reaching milestone of 20,000 diabetes screenings in 70 clinics February 26, 2024
FICCI Ladies Organization organized an interaction with one of the doyens of Indian IT industry Dr BVR Mohan ReddyFebruary 26, 2024
Former Secretary General of SCSC, Krishna Yedula conferred with Doctorate in HumanityFebruary 25, 2024
Project Champion School Games held February 25, 2024
Daksha 3.0, a nation level techno-test organised by Anurag University concludedFebruary 25, 2024
Mechanisation of Visakhapatnam Port is almost completeFebruary 24, 2024
Recovery Process After Contoura Surgery: Tips and Insights from an ExpertFebruary 24, 2024
Understanding Age-Related Macular Degeneration (AMD) and the Role of NutritionFebruary 24, 2024
Impact of Alcohol Consumption on Eye Health: Insights from a Senior Cataract SurgeonFebruary 23, 2024
Better health of healthcare workers in India : A Closer Look” Insights by Dr. Gopal Sharan MD & CEO of TRLS Healthcare ConsultancyFebruary 23, 2024
Chandrayaan Soft landing of India sent a strong message to the world not to take Indians light: Dr Prakash Chauhan, Director National Remote Sensing CenterFebruary 23, 2024
Dr Raj Nagarkar Leads Master Class On Robotic Surgery For Postgraduates At MASICON 2024 In NashikFebruary 23, 2024
Nanhaagyan Foundation Illuminates Pune with the Resplendent Healing Light Awards 2024February 23, 2024
Anifest India 2024: Pioneering Creativity in Pune's Animation Landscape"February 23, 2024
A Tie with a difference, promoting a cause, 17 SDGs of UNFebruary 22, 2024
Worldwide EndoMarch, Endo Run to raise mass awareness on Endometriosis!February 21, 2024
Uptick In Respiratory, and Cardiac Problems Due To Poor Air Quality In DelhiFebruary 21, 2024
Evidence shows risks associated with energy drinks in childrenFebruary 21, 2024
iHub-Data at IT-Hyderabad announces collaborative initiative with technical institutions for AI/ML training programsFebruary 20, 2024
Viatris Receives Global Minimized Risk of Antimicrobial Resistance Certification, Advancing its Commitment to Responsible Antibiotic ProductionFebruary 20, 2024